SYNC" that handily beats the deadly brain cancer, diffuse medial glioma (DMG), in mice. DMG has a prognosis of just 11 months ...

Intratumoral microbial antigens, which mimic tumor antigens, can be presented by human leukocyte antigen (HLA) molecules, ...

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies, today announced final data from the Phase 1/2 AUDREY study of ...

A gene rearrangement is referred to as "a hit," Westin told MedPage Today, adding that in the case of double-hit lymphoma, ...

A controlled syngeneic mouse study found that intracranial A20 B-cell lymphoma had stronger T-cell exhaustion, regulatory-cell expansion and dendritic-cell immunoregulation than subcutaneous tumors.

In a phase 1 trial, CD19/CD20/CD22 CAR T cells produced complete responses in 83% of patients with relapsed/refractory B-cell ...

BostonGene, developer of the leading AI model for tumor and immune biology, today announced a new research collaboration with the Medical University of South Carolina (MUSC). The collaboration will ...

Boryung completed enrollment of 44 patients for its Phase 2 trial of vosmolisib, a rare blood cancer drug, and aims to seek conditional approval after completing the trial in 2028.

A longitudinal study of 155 lymphoma patients found that older adults recovered memory function after CAR T-cell therapy ...

Diagnostic workup requires broad IHC immunophenotyping, Ki-67, and TP53 sequencing; MRD testing after induction must reach 10⁻⁶ sensitivity and increasingly dictates consolidation strategy. Frontline ...

Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics. The 2026 Society of Hematologic Oncology ...

A two-headed molecule designed by Stanford Medicine researchers hijacks one of the most common protein drivers of B-cell lymphoma, flipping it from its role as a promoter of cell growth into an ...